Dorman: Buy Before Margins Snap Back

Dorman is framed as undervalued, with projected earnings power of $10 per share in 2027 and a $160 price target. Q1 was weighed down by peak tariff costs under FIFO accounting, but management reaffirmed full-year guidance for 7-9% sales growth and expects operating margins to exit 2024 in the high teens. The setup implies margin normalization and growth acceleration into year-end.

Analysis

The key incremental point is not the headline earnings power, but the path to it: FIFO-related tariff compression creates a temporary optics problem that can mask a self-help margin inflection as inventory rolls through. That means the stock can re-rate before the reported margin fully normalizes, because investors will start capitalizing forward EPS once quarterly prints confirm the tariff overhang is clearing. The market is likely underappreciating how quickly a high-teens exit margin can compound into a much higher 2025-2027 earnings base if sales growth stays mid-single to high-single digits.

Competitively, the company is in a better position than peers that are still exposed to spot input costs or lack pricing power. If management can hold volume while passing through tariff pressure, weaker competitors may be forced into either margin sacrifice or share loss, especially in distribution channels where availability and fill rates matter more than absolute price. The second-order effect is that supply-chain normalization could actually widen the gap between best-positioned operators and the rest of the category over the next 2-4 quarters.

The main risk is a false dawn: if tariff costs re-accelerate, or if demand softens after the initial price adjustments, the expected margin rebound gets pushed out and the multiple de-rates on “peak earnings” skepticism. Near term, the stock can grind higher over the next 1-3 months on guidance credibility, but the bigger catalyst window is the next two quarters as reported margins begin to show the FIFO unwind. The contrarian view is that consensus may be too focused on the 2027 earnings target and not enough on the intermediate-year earnings bridge; if the bridge is cleaner than expected, upside to fair value can happen well before 2027.

Key Decisions for Investors

• Go long on pullbacks into the next 2-4 weeks if the stock weakens on noisy margin prints; use the tariff/FIFO overhang as an entry point rather than chase strength. Risk/reward improves if shares trade below implied forward EPS multiple expansion levels before the next quarterly release.
• If liquidity allows, buy a 6-12 month call spread to express the margin-normalization thesis with defined downside; this captures a multi-quarter re-rating while limiting exposure to another temporary cost spike.
• Pair trade: long Dorman vs. a peer with more direct exposure to spot-input inflation or weaker pricing power. The relative trade should work over 2-3 quarters if FIFO normalization is real and management execution remains clean.
• Set a tactical stop if the next update shows guide-down in sales growth or margins failing to inflect by year-end; that would imply the market was correct to discount the 2027 earnings bridge.
• If the stock rallies ahead of the next two prints, trim only if the market starts pricing the 2027 earnings target as already delivered; otherwise maintain core exposure because the catalyst path is still ahead of the estimate cycle.